Comparative Pharmacology
Head-to-head clinical analysis: GABAPENTIN ENCARBIL versus VIGAFYDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GABAPENTIN ENCARBIL versus VIGAFYDE.
GABAPENTIN ENCARBIL vs VIGAFYDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gabapentin encarbil is a prodrug of gabapentin, which binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing calcium influx and inhibiting neurotransmitter release.
Irreversible inhibitor of GABA transaminase, increasing brain GABA levels.
Oral gabapentin encarbil 600 mg once daily with evening meal, titrated based on response and tolerability, maximum 1200 mg once daily. Alternatively, 600 mg twice daily may be used; maximum 2400 mg/day.
Adults: 50 mg/kg/day orally divided twice daily; maximum dose 3 g/day.
None Documented
None Documented
The terminal elimination half-life of gabapentin derived from gabapentin encarbil is approximately 5-7 hours in patients with normal renal function. This half-life is prolonged in patients with renal impairment (up to 132 hours in anuria). Clinically, steady-state concentrations are achieved within 1-2 days. Twice-daily dosing is effective due to sustained exposure from the prodrug formulation.
Terminal elimination half-life is 6-8 hours in adults; in neonates, it is prolonged to 16-20 hours due to immature renal function.
Renal: Gabapentin encarbil is a prodrug of gabapentin. Following absorption, it is rapidly hydrolyzed to gabapentin. Gabapentin is primarily excreted unchanged in urine via glomerular filtration. Approximately 80-90% of a dose is recovered in urine as gabapentin, with the remainder as metabolites and minor amounts (≤1%) in feces. Biliary excretion is negligible.
Renal excretion of unchanged drug accounts for approximately 65-70% of elimination; biliary/fecal excretion is minimal (<5%).
Category A/B
Category C
Anticonvulsant
Anticonvulsant